Evidence map›Paper›PMID 26553708›Full record

ArticleScientific reports2015

Cell-free plasma hemoglobin removal by dialyzers with various permeability profiles.

Michael Hulko, Melanie Kunz, Mehmet Yildirim, Sandra Homeyer, Oliver Amon, Bernd Krause

Abstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael HulkoGambro Dialysatoren GmbH (part of Baxter International Inc.), Research &Development, 72379 Hechingen, Germany.
Melanie KunzGambro Dialysatoren GmbH (part of Baxter International Inc.), Research &Development, 72379 Hechingen, Germany.
Mehmet YildirimGambro Dialysatoren GmbH (part of Baxter International Inc.), Research &Development, 72379 Hechingen, Germany.
Sandra HomeyerGambro Dialysatoren GmbH (part of Baxter International Inc.), Research &Development, 72379 Hechingen, Germany.
Oliver AmonUniversity Hospital Tuebingen, Pediatric Nephrology, 72076 Tuebingen, Germany.
Bernd KrauseGambro Dialysatoren GmbH (part of Baxter International Inc.), Research &Development, 72379 Hechingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The release of hemoglobin from mechanically stressed erythrocytes into plasma is a general side effect of extracorporeal therapies, such as extracorporeal membrane oxygenation or hemodialysis. In many reported cases dialysis patients showed elevated cell-free plasma hemoglobin (CPH) levels which are associated with pathophysiological effects. In this in vitro study, the CPH clearance capacity of various filters with different permeability profiles was measured. Simulated dialysis treatments were conducted and clearance was calculated from variations in CPH concentrations over time by measuring plasma absorbance at 405 nm. Conventional high-flux filters exhibited no detectable clearance of CPH. High-flux filters with extended permeability exhibited clearances between 5.8 ± 1.2 and 12.7 ± 1.7 ml/min when tested with plasma and between 5.8 ± 1.2 and 11.3 ± 1.6 ml/min when tested with whole blood. septeX high-cutoff filters had clearances between 13.8 ± 1.8 and 15.5 ± 1.7 ml/min when tested with plasma and of 22.6 ± 2.9 ml/min when tested with whole blood. This study demonstrated that filters with extended permeability and the septeX filter enable CPH removal when used as in chronic and acute settings.

Indexed as

HemoglobinsPlasmaDialysisHumansMembranes, ArtificialPermeabilityHemoglobinsMembranes, Artificial

Identifiers

PMID26553708
PMCPMC4639840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.